Clinical trial · Interventional
Texture and Colour Enhancement Imaging in Improving Detection and Miss Rate of Premalignant Lesions
Impact of Texture and Color Enhancement Imaging on Detection and Miss Rate of Premalignant Lesions: A Multicentre, Randomized, Tandem Trial
NCT06515977CI-TRIAL-00079039unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Texture and Color Enhancement Imaging (TXI) is a newly developed image-enhancing endoscopy technology that has show potential in improving detection of colorectal lesions. This multicenter, randomized, tandem trial is aimed at evaluating whether TXI is superior to WLI endoscopy in terms of diagnosis of premalignant lesions.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenoma | Adenoma | ONTOLOGY_EXACT | 0.98 |
| Sessile Serrated Adenoma | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TXI followed by WLI (Group B) | Procedure | — | UNRESOLVED |
| TXI (Group A) | Procedure | — | UNRESOLVED |
| WLI followed by TXI (Group D) | Procedure | — | UNRESOLVED |
| WLI (Group C) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- TXI (Group A)
- description
- Arm undergoing colonoscopy with TXI
- interventionNames
- Procedure: TXI (Group A)
- type
- EXPERIMENTAL
- label
- TXI followed by WLI (Group B)
- description
- Arm undergoing initial inspection under TXI first, followed by second inspection with WLI
- interventionNames
- Procedure: TXI followed by WLI (Group B)
- type
- ACTIVE_COMPARATOR
- label
- WLI (Group C)
- description
- Arm undergoing normal colonoscopy with WLI
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 45 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: patients aged 45-85 years and scheduled for screening colonoscopy who provided written informed consent Exclusion Criteria: Surveillance, diagnostic or therapeutic colonoscopy Patients with an already known or suspected colorectal tumour Patients with alarming symptoms and signs, including haematochezia, melena, weight loss or anaemia without specific causes, an abdominal mass and positive digital rectal examination Pregnant or lactating women Patients with gastrointestinal tract obstruction Patients with inflammatory bowel diseases, hereditary CRC syndromes or serrated polyposis syndrome Patients with abnormal blood coagulation or taking antiplatelets or anticoagulants within 7 days before colonoscopy Patients with failed cecal intubation Patients with poor bowel preparation quality that necessitated a second bowel preparation Patients with a history of colonic resection
References
Publications (3)
- BACKGROUNDWei J, Zhao S, Bai Y. Impact of Texture and Color Enhancement Imaging on Adenoma and Sessile Serrated Lesion Detection: Much More to Explore. Gastroenterology. 2024 Jul;167(2):413-414. doi: 10.1053/j.gastro.2024.01.014. Epub 2024 Jan 13. No abstract available. PMID 38224857
- BACKGROUNDAntonelli G, Bevivino G, Pecere S, Ebigbo A, Cereatti F, Akizue N, Di Fonzo M, Coppola M, Barbaro F, Walter BM, Sharma P, Caruso A, Okimoto K, Antenucci C, Matsumura T, Zerboni G, Grossi C, Meinikheim M, Papparella LG, Correale L, Costamagna G, Repici A, Spada C, Messmann H, Hassan C, Iacopini F. Texture and color enhancement imaging versus high definition white-light endoscopy for detection of colorectal neoplasia: a randomized trial. Endoscopy. 2023 Dec;55(12):1072-1080. doi: 10.1055/a-2129-7254. Epub 2023 Jul 14. PMID 37451283
- BACKGROUNDYoung E, Rajagopalan A, Tee D, Sathananthan D, Hoile S, Singh R. Texture and Color Enhancement Imaging Improves Colonic Adenoma Detection: A Multicenter Randomized Controlled Trial. Gastroenterology. 2024 Feb;166(2):338-340.e3. doi: 10.1053/j.gastro.2023.10.008. Epub 2023 Oct 14. PMID 37839498